Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial

23 hours ago 1

Sheryar Siddiq

Tue, February 3, 2026 astatine 5:55 AM CST 1 min read

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to bargain according to apical investors. Truist Securities accrued its terms people for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $230 from $220 connected January 12, preserving a Buy standing connected the company. The emergence follows practice-changing results from the HERIZON-GEA trial, which Truist utilized to warrant adjusting its Ziihera estimations higher.

In bid to get a wide statement for first-line gastroesophageal adenocarcinoma (GEA) arsenic some doublet and triplet therapy with precedence review, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) executives intends to record a supplemental Biologics License Application (sBLA) successful the archetypal fractional of 2026.

After clearance based connected objective data, Truist Securities anticipates beardown commercialized adoption, probable adoption successful NCCN guidelines, implicit 90% prescriber crossover betwixt GEA and biliary tract crab (BTC), and compatibility of PD-1 inhibitor selection.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is simply a biopharmaceutical institution that develops treatments for superior illnesses. Its cardinal products see Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

While we admit the imaginable of JAZZ arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.